Please login to the form below

Not currently logged in
Email:
Password:

Merkel cell carcinoma

This page shows the latest Merkel cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most ... Bavencio is also approved for the

Latest news

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...